Moderna Inc. (MRNA)
Moderna Statistics
Share Statistics
Moderna has 385.82M shares outstanding. The number of shares has increased by 0.67% in one year.
| Shares Outstanding | 385.82M |
| Shares Change (YoY) | 0.67% |
| Shares Change (QoQ) | 0.26% |
| Owned by Institutions (%) | 72.03% |
| Shares Floating | 341.66M |
| Failed to Deliver (FTD) Shares | 9 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 49.8M, so 12.88% of the outstanding shares have been sold short.
| Short Interest | 49.8M |
| Short % of Shares Out | 12.88% |
| Short % of Float | 17.89% |
| Short Ratio (days to cover) | 6.03 |
Valuation Ratios
The PE ratio is -4.48 and the forward PE ratio is -3.51. Moderna's PEG ratio is 0.18.
| PE Ratio | -4.48 |
| Forward PE | -3.51 |
| PS Ratio | 4.93 |
| Forward PS | 1.3 |
| PB Ratio | 1.46 |
| P/FCF Ratio | -3.94 |
| PEG Ratio | 0.18 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Moderna.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.67, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.67 |
| Quick Ratio | 3.62 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | -0.21 |
| Debt / FCF | -0.18 |
| Interest Coverage | -164.38 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $557.93K |
| Profits Per Employee | $-613.97K |
| Employee Count | 5,800 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 12.51 |
Taxes
| Income Tax | -46M |
| Effective Tax Rate | 1.28% |
Stock Price Statistics
The stock price has increased by -74.82% in the last 52 weeks. The beta is 2.23, so Moderna's price volatility has been higher than the market average.
| Beta | 2.23 |
| 52-Week Price Change | -74.82% |
| 50-Day Moving Average | 30.69 |
| 200-Day Moving Average | 54.16 |
| Relative Strength Index (RSI) | 47 |
| Average Volume (20 Days) | 10.77M |
Income Statement
In the last 12 months, Moderna had revenue of 3.24B and earned -3.56B in profits. Earnings per share was -9.27.
| Revenue | 3.24B |
| Gross Profit | 1.77B |
| Operating Income | -3.94B |
| Net Income | -3.56B |
| EBITDA | -3.39B |
| EBIT | -3.58B |
| Earnings Per Share (EPS) | -9.27 |
Balance Sheet
The company has 1.93B in cash and 710M in debt, giving a net cash position of 1.22B.
| Cash & Cash Equivalents | 1.93B |
| Total Debt | 710M |
| Net Cash | 1.22B |
| Retained Earnings | 10.04B |
| Total Assets | 14.14B |
| Working Capital | 5.89B |
Cash Flow
In the last 12 months, operating cash flow was -3B and capital expenditures -1.05B, giving a free cash flow of -4.05B.
| Operating Cash Flow | -3B |
| Capital Expenditures | -1.05B |
| Free Cash Flow | -4.05B |
| FCF Per Share | -10.56 |
Margins
Gross margin is 54.76%, with operating and profit margins of -121.91% and -110.04%.
| Gross Margin | 54.76% |
| Operating Margin | -121.91% |
| Pretax Margin | -111.46% |
| Profit Margin | -110.04% |
| EBITDA Margin | -104.88% |
| EBIT Margin | -121.91% |
| FCF Margin | -125.31% |
Dividends & Yields
MRNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MRNA is $50.5, which is 85.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $50.5 |
| Price Target Difference | 85.7% |
| Analyst Consensus | Hold |
| Analyst Count | 20 |
Scores
| Altman Z-Score | 2.84 |
| Piotroski F-Score | 2 |